Blueprint Medicines
Developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases.
Launch date
Employees
Market cap
AUD8.2b
Enterprise valuation
AUD7.8b (Public information from Sep 2024)
Share price
$89.33 BPMC
Cambridge Massachusetts (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 794m | 180m | 204m | 249m | 496m | 687m | 936m |
| % growth | 1093 % | (77 %) | 13 % | 22 % | 99 % | 39 % | 36 % |
| EBITDA | 309m | (634m) | (529m) | (470m) | (227m) | (93.1m) | 98.5m |
| % EBITDA margin | 39 % | (352 %) | (259 %) | (189 %) | (46 %) | (14 %) | 11 % |
| Profit | 314m | (644m) | (558m) | (507m) | (98.2m) | (117m) | 51.9m |
| % profit margin | 40 % | (358 %) | (273 %) | (203 %) | (20 %) | (17 %) | 6 % |
| EV / revenue | 6.8x | 32.4x | 8.9x | 20.6x | 10.6x | 7.7x | 5.5x |
| EV / EBITDA | 17.4x | -9.2x | -3.4x | -10.9x | -23.3x | -56.7x | 52.0x |
| R&D budget | 327m | 601m | 477m | 428m | - | - | - |
| R&D % of revenue | 41 % | 334 % | 234 % | 172 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$40.0m | Series A | ||
N/A | Early VC | ||
$25.0m | Series B | ||
$50.0m | Series C | ||
| N/A | $147m Valuation: $398m | IPO | |
| N/A | $135m | Post IPO Equity | |
| N/A | $216m | Post IPO Equity | |
| N/A | $326m | Post IPO Equity | |
| N/A | $327m | Post IPO Equity | |
$1.3b Valuation: $1.3b 6.9x EV/LTM Revenues -2.0x EV/LTM EBITDA | Post IPO Equity | ||
| Total Funding | AUD178m | ||
Related Content
Recent News about Blueprint Medicines
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Blueprint Medicines
Edit
ACQUISITION by Blueprint Medicines Nov 2021